Jun D Zhang

US Patent:

6683894, Jan 27, 2004

Filed:

Apr 19, 2000

Appl. No.:

09/552579

Inventors:

Hyo Sang Lee - Silver Spring MD
Coorg R. Prasad - Silver Spring MD
Jun Zhang - Ellicott City MD

Assignee:

Science Engineering Services, Inc. - Burtonsville MD

International Classification:

H01S 310

US Classification:

372 20, 372 21, 372 22, 372 10, 372 30, 372101, 372105

Abstract:

A diode pumped solid state laser/OPO system widely tunable in mid infrared spectrum for infrared matrix assisted laser desorption/ionization (MALDI) mass spectroscopy is disclosed. Up to a few tens of milli-Joule, short pulse, tunable near infrared laser pulse is generated from an all solid state laser at a high pulse repetition rate up to one kHz. The tunable near-infrared laser pumps a Quasi-Phase Matching (QPM) OPO system to further shift the wavelength to the mid-IR range and to broaden the tuning range to as much as 3 m to effectively generate a widely tunable spectral output. The wide range tuning of the infrared output is accomplished by a narrow range tuning of the pump laser. The pump laser output is generated by a diode pumped tunable solid state laser module using either a Yb:YAG crystal or any other efficient tunable laser crystals. The wavelength range (2-5 m) covered by the solid state laser system is optimum for MALDI applications. This wavelength range is especially beneficial for large mass DNA analysis.

US Patent:

6811773, Nov 2, 2004

Filed:

May 15, 2000

Appl. No.:

09/571013

Inventors:

Reiner L. Gentz - Silver Spring MD
Brent L. Kreider - Germantown MD
Jun Zhang - Bethesda MD
Michael Antonaccio - Germantown MD
Donna Mendrick - Mt. Airy MD
Pablo Jimenez - Ellicott City MD
Vikram Patel - Germantown MD
Craig A. Rosen - Laytonsville MD
Mark D. Adams - North Potomac MD
Haodong Li - Gaithersburg MD
Steven M. Ruben - Olney MD

Assignee:

Human Genome Sciences, Inc. - Rockville MD

International Classification:

A61K 3819

US Classification:

424 851, 530324, 514 2, 514 8, 514 12, 536 235, 435 695, 435 697, 435 711, 435 712, 435471, 4352523, 43525411, 4353201

Abstract:

There are disclosed therapeutic compositions and methods using a human monocyte-colony inhibitory factor (M-CIF) polypeptide (previously termed MIP1- chemokine 1(CK1 or ckb-1)), as well as ioslated nucleic acid molecules encoding M-CIF, and vectors, host cells and recombinant methods for producing the same.

US Patent:

20030049640, Mar 13, 2003

Filed:

Dec 27, 2001

Appl. No.:

10/033741

Inventors:

Eugene Herman - Takoma Park MD, US
Gordon Holt - Gaithersburg MD, US
Frank Sistare - Ellicott City MD, US
Jun Zhang - Rockville MD, US

International Classification:

C12Q001/68
G01N033/53
G01N033/542
G01N033/557

US Classification:

435/006000, 435/007900, 436/517000

Abstract:

The present invention provides methods and compositions for screening, diagnosis and prognosis of vascular response, for monitoring the effectiveness of vascular response treatment, identifying patients most likely to respond to a particular therapeutic treatment and for drug development. In particular, the screening of drug candidates for their ability to induce a vascular response. Vascular Response-Associated Features (VRFs), detectable by two-dimensional electrophoresis of blood, serum or plasma are described. The invention further provides Vascular Response-Associated Protein Isoforms (VRPIs) detectable in blood, serum or plasma, preparations comprising isolated VRPIs, antibodies immunospecific for VRPIs, and kits comprising the aforesaid.

US Patent:

20030092197, May 15, 2003

Filed:

Dec 27, 2001

Appl. No.:

10/033662

Inventors:

Eugene Herman - Takoma Park MD, US
Gordon Holt - Gaithersburg MD, US
Frank Sistare - Ellicott City MD, US
Jun Zhang - Rockville MD, US

International Classification:

G01N033/557
A61K031/00

US Classification:

436/517000, 514/001000

Abstract:

The present invention provides methods and compositions for screening, diagnosis and prognosis of Cardiac Response, for monitoring the effectiveness of Cardiac Response treatment and for drug development. Cardiac Response-Associated Features (CRFs) detectable by two-dimensional electrophoresis of blood are described. The invention further provides Cardiac Response-Associated Protein Isoforms (CRPIs) detectable in biological sample preparations comprising isolated CRPIs, antibodies specific for CRPIs and kits comprising the aforesaid.

US Patent:

20210162005, Jun 3, 2021

Filed:

Feb 10, 2021

Appl. No.:

17/172202

Inventors:

- Rockville MD, US
Jun ZHANG - Ellicott City MD, US

International Classification:

A61K 38/17
C07K 14/47
C12N 9/02
C12N 15/86
A61K 47/64
A61P 25/14
A61K 47/42
C07K 14/76
C12N 15/11
C12N 15/113
C12N 15/85

Abstract:

A fusion protein is described, comprising a first N-terminal signal peptide sequence, a second peptide sequence C-terminal to the signal peptide sequence, and a third peptide sequence C-terminal to the second peptide sequence; wherein one of the second peptide sequence and the third peptide sequence is an RdCVF-short peptide sequence and the other is a hydrophilic peptide sequence. After translation the signal peptide is cleaved, leaving a fusion protein comprising the second peptide sequence and the third peptide sequence minus the signal peptide. Also described are nucleic acids and expression vectors encoding the fusion protein, cells comprising the nucleic acid or expression vector, as well as methods of treatment and uses of the fusion protein, nucleic acid, and expression vector. The fusion protein can be produced in vitro by culturing the cells of this invention under conditions allowing for expression and secretion of the encoded fusion protein, and isolating the fusion protein from the cell culture.

US Patent:

20190151410, May 23, 2019

Filed:

Oct 11, 2017

Appl. No.:

16/301764

Inventors:

- Rockville MD, US
Jun ZHANG - Ellicott City MD, US

International Classification:

A61K 38/17
C07K 14/47
C12N 15/85
C12N 15/11
C07K 14/76
C12N 15/113
A61P 25/14
A61K 47/42
A61K 47/64

Abstract:

A fusion protein is described, comprising a first N-terminal signal peptide sequence, a second peptide sequence C-terminal to the signal peptide sequence, and a third peptide sequence C-terminal to the second peptide sequence; wherein one of the second peptide sequence and the third peptide sequence is an RdCVF-short peptide sequence and the other is a hydrophilic peptide sequence. After translation the signal peptide is cleaved, leaving a fusion protein comprising the second peptide sequence and the third peptide sequence minus the signal peptide. Also described are nucleic acids and expression vectors encoding the fusion protein, cells comprising the nucleic acid or expression vector, as well as methods of treatment and uses of the fusion protein, nucleic acid, and expression vector. The fusion protein can be produced in vitro by culturing the cells of this invention under conditions allowing for expression and secretion of the encoded fusion protein, and isolating the fusion protein from the cell culture.

Address:

7902 Red Barn Way, Elkridge, MD 21075

VIN:

4T1BE46K17U681522

Make:

TOYOTA

Model:

CAMRY

Year:

2007